Organogenesis Holdings (STU:2PQ) Construction In Progress: €0.0 Mil (As of Mar. 2026)


STU:2PQ Organogenesis Holdings Inc STU:2PQ
67 GF Score
Price €2.10
GF Value €2.74
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Organogenesis Holdings Construction In Progress?

Organogenesis Holdings STU:2PQ -0.94% 67 Construction In Progress is €0.0 Mil as of Mar. 2026. GuruFocus rates STU:2PQ with a GF Score™ of 67/100 and a GF Value™ of €2.74 (Modestly Undervalued). The stock has 5 warning signs investors should review.

Organogenesis Holdings's quarterly construction in progress declined from Sep. 2025 (€23.5 Mil) to Dec. 2025 (€22.8 Mil) and declined from Dec. 2025 (€22.8 Mil) to Mar. 2026 (€0.0 Mil).

Organogenesis Holdings's annual construction in progress declined from Dec. 2023 (€54.2 Mil) to Dec. 2024 (€20.9 Mil) but then increased from Dec. 2024 (€20.9 Mil) to Dec. 2025 (€22.8 Mil).

Organogenesis Holdings Construction In Progress Historical Data

* Premium members only.

The historical data trend for Organogenesis Holdings's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Organogenesis Holdings Construction In Progress Chart

Organogenesis Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Construction In Progress
Get a 7-Day Free Trial Premium Member Only Premium Member Only 42.00 61.89 54.16 20.90 22.84

Organogenesis Holdings Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Construction In Progress Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 21.98 20.75 23.47 22.84 0.00
STU:2PQ
67GF Score
Organogenesis Holdings Inc STU:2PQ
Construction In Progress is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Organogenesis Holdings Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

What does a Construction In Progress of €0.0 Mil mean?
Organogenesis Holdings (STU:2PQ) has a Construction In Progress of €0.0 Mil as of Mar. 2026. Construction in Progress records the amount of construction work that is not complete. View historical data on Organogenesis Holdings and its competitors.
Is Organogenesis Holdings' Construction In Progress too high?
Organogenesis Holdings' current Construction In Progress is €0.0 Mil. Overall, Organogenesis Holdings has a GF Score™ of 67/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Organogenesis Holdings' Construction In Progress compare to TKNO and AKBA?
Organogenesis Holdings' Construction In Progress of €0.0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Construction In Progress for a Drug Manufacturers company?
A good Construction In Progress depends on the Drug Manufacturers industry context. However, Construction In Progress should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Construction In Progress mean?
A high Construction In Progress can signal that a stock is expensive relative to its fundamentals. Construction in Progress records the amount of construction work that is not complete. View historical data on Organogenesis Holdings and its competitors. Organogenesis Holdings's current Construction In Progress is €0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Organogenesis Holdings stock overvalued right now?
Based on GuruFocus' analysis, Organogenesis Holdings (STU:2PQ) is currently considered Modestly Undervalued. The stock's GF Value™ is €2.74, compared to a current price of €2.10 — trading 23.4% below its estimated fair value. The current Construction In Progress is €0.0 Mil. Organogenesis Holdings' overall GF Score™ is 67/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Construction In Progress calculated?
Construction In Progress is calculated from a company's financial statements. For Organogenesis Holdings (STU:2PQ), the current Construction In Progress is €0.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Organogenesis Holdings (STU:2PQ) Overvalued in 2026?

Based on GuruFocus' analysis, Organogenesis Holdings stock appears to be undervalued. The current stock price of €2.10 is trading 23.4% below its estimated GF Value™ of €2.74. GuruFocus considers Organogenesis Holdings to be Modestly Undervalued.

Key valuation signals for STU:2PQ:

  • Construction In Progress: €0.0 Mil
  • GF Value™: €2.74 vs. price of €2.10 (23.4% below fair value)
  • GF Score™: 67/100 with 5 warning signs

No single metric tells the full story. See the STU:2PQ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Organogenesis Holdings Business Description

Other Exchanges ORGO:USA2PQ:Germany
Address 85 Dan Road, Canton, MA, USA, 02021
Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting. The company operates in a single segment, that is, regenerative medicine.
67GF Score

Get the complete analysis for STU:2PQ

Construction In Progress is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.10
Price
€2.74
GF Value